stockrow
Friday 6 November 2026
Export TNDM’s income statement to Excel — free account
Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024.
- Revenue
- +13.8%
- EPS
- +67.7%
- Free cash flow
- −232.0%
- Total debt
- +94.9%
Quarter to September 2026, against a year earlier
16.78
1.21
−6.73%
Follow TNDM
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.06 | 1.00 | 1.28 | 1.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1,387.05) | (30.07) | 118.62 | 151.08 | |
P/B ratio |
8.41 | 7.99 | 9.90 | 9.53 | |
Price to Tangible BV |
8.46 | 8.04 | 9.97 | 9.59 | |
EV/Sales |
1.20 | 1.14 | 1.31 | 1.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(88.75) | (215.09) | 68.47 | (153.92) | |
EV/FCF |
(12.29) | (12.40) | (18.43) | (15.13) | |
Quick Ratio |
2.43 | 2.44 | 2.87 | 1.89 | |
Current Ratio |
3.21 | 3.18 | 3.58 | 2.55 | |
Net Debt/EBITDA |
0.00 | (15.29) | (2.41) | 1.51 | |
Debt/Assets |
52.04% | 52.21% | 52.17% | 35.19% | |
Debt/Equity |
4.47 | 4.62 | 4.55 | 2.00 | |
Asset Turnover |
1.06 | 1.03 | 0.99 | 1.10 | |
Operating CF/Net income |
0.12 | 1.64 | (0.54) | (16.62) | |
Capex/Depreciation |
0.00 | (0.96) | (1.45) | (2.09) | |
Interest Coverage |
(1.03) | (5.63) | (7.91) | 4.00 | |
Research and Development Expense of Revenue |
0.00% | 18.44% | 18.62% | 15.86% | |
Selling, General and Administrative Expense of Revenue |
40.17% | 43.86% | 43.76% | 38.95% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.60% | 6.18% | 6.33% | 6.93% | |
Graham Net Nets |
(0.18) | (0.21) | (0.10) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.41%) | (6.16%) | (7.30%) | (13.97%) | |
Free Cash Flow Yield |
(9.29%) | (9.20%) | (5.56%) | (6.69%) | |
Revenue per Share |
4.07 | 3.69 | 3.61 | 4.32 | |
Operating CF per Share |
(0.01) | (0.50) | 0.16 | 0.15 | |
Capex per Share |
(0.07) | (0.06) | (0.09) | (0.10) | |
Free Cash Flow per Share |
(0.08) | (0.56) | 0.07 | 0.05 | |
Cash per Share |
6.36 | 6.61 | 8.34 | 4.35 | |
Shareholders Equity per Share |
1.94 | 1.89 | 1.94 | 2.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.94 | 1.89 | 1.94 | 2.31 | |
Free Cash Flow |
(5.51) | (38.68) | 4.79 | 3.10 | |
Working Capital |
564.65 | 551.63 | 639.14 | 375.42 | |
Capital Expenditures |
(4.69) | (4.05) | (6.27) | (6.68) | |
Net Current Asset Value |
(203.68) | (219.17) | (133.89) | (107.80) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
152.98 | 145.25 | 133.62 | 140.04 | |
Average Payables |
61.14 | 59.98 | 59.83 | 45.90 | |
Average Inventory |
140.20 | 138.84 | 133.78 | 139.19 | |
Average Assets |
1,017.07 | 1,014.97 | 1,037.77 | 924.39 | |
Average Common Equity |
134.03 | 131.84 | 143.85 | 209.13 |
Columns are period end dates · fundamentals updated 5 Nov 2026